Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
Pragmatic Replication of the Heads Up Head-to-head Study of Upadacitinib and Dupilumab With TREATgermany Registry Data
Technische Universität Dresden
240 participants
Aug 2, 2021
OBSERVATIONAL
Conditions
Summary
The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001/jamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).
Eligibility
Inclusion Criteria4
- Chronic AD with onset of symptoms at least 3 years prior to baseline
- Meets UK working party criteria
- EASI score ≥ 16
- ≥ 10% body surface area (BSA) of AD involvement at baseline ("therapy start") visit
Exclusion Criteria1
- contraindications according to upadacitinib or dupilumab labeling
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
30 mg tablet daily
300 mg injection every other week
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06937788